In addition, human breast cancer cells overexpressing HER2 or acquiring resistance to the oestrogen receptor (ER) antagonist, fulvestrant (Faslodex, ICI 182,780), have been reported to be particularly sensitive to gefitinib (McClelland et al, 2001; Moulder et al, 2001). The gene discussed is ERBB2; the disease is breast carcinoma.